{"id":"mixed-amphetamine-salts-er","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Insomnia"},{"rate":"10-25%","effect":"Decreased appetite"},{"rate":"5-15%","effect":"Headache"},{"rate":"5-15%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Nervousness/anxiety"},{"rate":"5-10%","effect":"Tachycardia"},{"rate":"5-10%","effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination of amphetamine isomers acts as a sympathomimetic amine that stimulates the release of catecholamines (dopamine and norepinephrine) from presynaptic neurons and inhibits their reuptake, leading to increased synaptic concentrations. The extended-release formulation provides sustained therapeutic levels throughout the day. This mechanism improves executive function, attention span, and impulse control in patients with attention-deficit/hyperactivity disorder (ADHD).","oneSentence":"Mixed amphetamine salts increase the release and block the reuptake of dopamine and norepinephrine in the central nervous system, enhancing attention and reducing impulsivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:41.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT01986075","phase":"PHASE1, PHASE2","title":"A Sequenced Behavioral and Medication Intervention for Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-01","conditions":"Cocaine Dependence","enrollment":145},{"nctId":"NCT00393042","phase":"PHASE3","title":"Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2006-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":77}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLEPHAROSPASM"},{"count":1,"reaction":"DISTURBANCE IN ATTENTION"},{"count":1,"reaction":"DRUG EFFECT INCOMPLETE"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"FEELING ABNORMAL"},{"count":1,"reaction":"IMPULSIVE BEHAVIOUR"},{"count":1,"reaction":"INTENTIONAL PRODUCT USE ISSUE"},{"count":1,"reaction":"LOGORRHOEA"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"PRODUCT SUBSTITUTION ISSUE"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adderall XR"],"phase":"phase_3","status":"active","brandName":"Mixed Amphetamine Salts, ER","genericName":"Mixed Amphetamine Salts, ER","companyName":"Seattle Children's Hospital","companyId":"seattle-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mixed amphetamine salts increase the release and block the reuptake of dopamine and norepinephrine in the central nervous system, enhancing attention and reducing impulsivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}